Cargando…
Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma
BACKGROUND: Tumours with no evidence of neuroendocrine transformation histologically but harbouring neuroendocrine features are collectively referred to as non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED). Investigating the mechanisms underlying NED is conducive to design...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195954/ https://www.ncbi.nlm.nih.gov/pubmed/37199872 http://dx.doi.org/10.1007/s12672-023-00693-4 |
_version_ | 1785044239995895808 |
---|---|
author | Liu, Hao Han, Yan Liu, Zhantao Gao, Liping Yi, Tienan Yu, Yuandong Wang, Yu Qu, Ping Xiang, Longchao Li, Yong |
author_facet | Liu, Hao Han, Yan Liu, Zhantao Gao, Liping Yi, Tienan Yu, Yuandong Wang, Yu Qu, Ping Xiang, Longchao Li, Yong |
author_sort | Liu, Hao |
collection | PubMed |
description | BACKGROUND: Tumours with no evidence of neuroendocrine transformation histologically but harbouring neuroendocrine features are collectively referred to as non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED). Investigating the mechanisms underlying NED is conducive to designing appropriate treatment options for NSCLC patients. METHODS: In the present study, we integrated multiple lung cancer datasets to identify neuroendocrine features using a one-class logistic regression (OCLR) machine learning algorithm trained on small cell lung cancer (SCLC) cells, a pulmonary neuroendocrine cell type, based on the transcriptome of NSCLC and named the NED index (NEDI). Single-sample gene set enrichment analysis, pathway enrichment analysis, ESTIMATE algorithm analysis, and unsupervised subclass mapping (SubMap) were performed to assess the altered pathways and immune characteristics of lung cancer samples with different NEDI values. RESULTS: We developed and validated a novel one-class predictor based on the expression values of 13,279 mRNAs to quantitatively evaluate neuroendocrine features in NSCLC. We observed that a higher NEDI correlated with better prognosis in patients with LUAD. In addition, we observed that a higher NEDI was significantly associated with reduced immune cell infiltration and immune effector molecule expression. Furthermore, we found that etoposide-based chemotherapy might be more effective in the treatment of LUAD with high NEDI values. Moreover, we noted that tumours with low NEDI values had better responses to immunotherapy than those with high NEDI values. CONCLUSIONS: Our findings improve the understanding of NED and provide a useful strategy for applying NEDI-based risk stratification to guide decision-making in the treatment of LUAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00693-4. |
format | Online Article Text |
id | pubmed-10195954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-101959542023-05-20 Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma Liu, Hao Han, Yan Liu, Zhantao Gao, Liping Yi, Tienan Yu, Yuandong Wang, Yu Qu, Ping Xiang, Longchao Li, Yong Discov Oncol Research BACKGROUND: Tumours with no evidence of neuroendocrine transformation histologically but harbouring neuroendocrine features are collectively referred to as non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED). Investigating the mechanisms underlying NED is conducive to designing appropriate treatment options for NSCLC patients. METHODS: In the present study, we integrated multiple lung cancer datasets to identify neuroendocrine features using a one-class logistic regression (OCLR) machine learning algorithm trained on small cell lung cancer (SCLC) cells, a pulmonary neuroendocrine cell type, based on the transcriptome of NSCLC and named the NED index (NEDI). Single-sample gene set enrichment analysis, pathway enrichment analysis, ESTIMATE algorithm analysis, and unsupervised subclass mapping (SubMap) were performed to assess the altered pathways and immune characteristics of lung cancer samples with different NEDI values. RESULTS: We developed and validated a novel one-class predictor based on the expression values of 13,279 mRNAs to quantitatively evaluate neuroendocrine features in NSCLC. We observed that a higher NEDI correlated with better prognosis in patients with LUAD. In addition, we observed that a higher NEDI was significantly associated with reduced immune cell infiltration and immune effector molecule expression. Furthermore, we found that etoposide-based chemotherapy might be more effective in the treatment of LUAD with high NEDI values. Moreover, we noted that tumours with low NEDI values had better responses to immunotherapy than those with high NEDI values. CONCLUSIONS: Our findings improve the understanding of NED and provide a useful strategy for applying NEDI-based risk stratification to guide decision-making in the treatment of LUAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00693-4. Springer US 2023-05-18 /pmc/articles/PMC10195954/ /pubmed/37199872 http://dx.doi.org/10.1007/s12672-023-00693-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Liu, Hao Han, Yan Liu, Zhantao Gao, Liping Yi, Tienan Yu, Yuandong Wang, Yu Qu, Ping Xiang, Longchao Li, Yong Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma |
title | Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma |
title_full | Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma |
title_fullStr | Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma |
title_full_unstemmed | Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma |
title_short | Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma |
title_sort | depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195954/ https://www.ncbi.nlm.nih.gov/pubmed/37199872 http://dx.doi.org/10.1007/s12672-023-00693-4 |
work_keys_str_mv | AT liuhao depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT hanyan depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT liuzhantao depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT gaoliping depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT yitienan depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT yuyuandong depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT wangyu depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT quping depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT xianglongchao depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma AT liyong depictionofneuroendocrinefeaturesassociatedwithimmunotherapyresponseusinganoveloneclasspredictorinlungadenocarcinoma |